FANJ
LGND icon

Financial Architects (New Jersey)’s Ligand Pharmaceuticals LGND Stock Holding History

Financial Architects (New Jersey)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-160
Closed -$27K – 1424
2018
Q3 		$27K Buy
+160
New +$24.1K ﹤0.01% 834

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Financial Architects (New Jersey)'s LGND Position: Q4 2017 in Review

Financial Architects (New Jersey) sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 3,206 shares — an estimated $272K sold.

Financial Architects (New Jersey) first reported a position in LGND in Q4 2014 and held it in 6 quarters. The position peaked at $434K in Q4 2015. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

  • Financial Architects (New Jersey) reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 3,206 Ligand Pharmaceuticals shares in Q4 2017, an estimated $272K.
  • Financial Architects (New Jersey) first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Financial Architects (New Jersey)'s Ligand Pharmaceuticals position peaked at $434K in Q4 2015.
  • 298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2017, filed 12 Feb 2018.